Your browser is no longer supported. Please, upgrade your browser.
Settings
FGEN FibroGen, Inc. daily Stock Chart
FGEN [NASD]
FibroGen, Inc.
Index- P/E- EPS (ttm)-1.32 Insider Own1.20% Shs Outstand88.22M Perf Week-8.61%
Market Cap3.20B Forward P/E- EPS next Y-1.04 Insider Trans-11.83% Shs Float81.70M Perf Month-8.78%
Income-109.90M PEG- EPS next Q-0.21 Inst Own73.50% Short Float8.18% Perf Quarter-22.02%
Sales257.10M P/S12.45 EPS this Y13.60% Inst Trans4.78% Short Ratio8.95 Perf Half Y-17.18%
Book/sh5.20 P/B6.47 EPS next Y-20.90% ROA-12.60% Target Price58.22 Perf Year-7.15%
Cash/sh5.63 P/C5.98 EPS next 5Y- ROE-20.00% 52W Range22.65 - 48.95 Perf YTD-21.54%
Dividend- P/FCF- EPS past 5Y22.50% ROI-15.30% 52W High-31.26% Beta1.50
Dividend %- Quick Ratio11.00 Sales past 5Y13.30% Gross Margin99.20% 52W Low48.57% ATR2.03
Employees531 Current Ratio11.10 Sales Q/Q2.10% Oper. Margin-47.20% RSI (14)42.28 Volatility5.25% 5.85%
OptionableYes Debt/Eq0.14 EPS Q/Q-67.60% Profit Margin-42.70% Rel Volume1.17 Prev Close33.44
ShortableYes LT Debt/Eq0.11 EarningsMay 07 AMC Payout- Avg Volume747.01K Price33.65
Recom2.10 SMA20-7.58% SMA50-5.45% SMA200-15.53% Volume876,362 Change0.63%
May-01-20Initiated Cowen Market Perform $40
Apr-27-20Initiated BofA/Merrill Neutral $45
May-29-19Resumed Goldman Neutral
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Citigroup Buy
Sep-23-15Initiated Lake Street Hold $25
Jul-29-15Initiated Citigroup Buy $37
Jul-20-15Upgrade Goldman Neutral → Buy
Dec-09-14Initiated Stifel Buy $39
Dec-09-14Initiated RBC Capital Mkts Outperform $38
May-27-20 07:00AM  
May-21-20 07:00AM  
May-20-20 10:00PM  
May-11-20 06:32AM  
May-09-20 05:01PM  
01:42AM  
May-08-20 07:00AM  
May-07-20 08:40PM  
04:01PM  
11:24AM  
May-06-20 08:43AM  
May-03-20 10:17AM  
Apr-30-20 12:33PM  
Apr-24-20 07:00AM  
Apr-21-20 05:31PM  
Apr-20-20 07:00AM  
Mar-27-20 02:52PM  
Mar-24-20 04:23PM  
Mar-04-20 07:07AM  
Mar-03-20 08:13PM  
05:50PM  
Mar-02-20 05:15PM  
04:01PM  
Feb-24-20 12:30PM  
Feb-18-20 07:00AM  
Feb-12-20 09:45AM  
09:18AM  
Feb-11-20 05:00PM  
08:00AM  
Feb-03-20 03:42PM  
Jan-31-20 09:12AM  
Jan-30-20 12:01AM  
Jan-13-20 05:59PM  
Jan-06-20 06:03PM  
07:00AM  
Dec-24-19 08:55AM  
Dec-23-19 05:42PM  
07:00AM  
Dec-17-19 06:45AM  
Dec-06-19 10:03AM  
Dec-02-19 07:00AM  
Nov-15-19 02:20PM  
Nov-14-19 07:42PM  
05:24PM  
Nov-13-19 08:03PM  
07:00PM  
06:19PM  
02:00PM  
Nov-11-19 05:15PM  
05:10PM  
04:01PM  
09:21AM  
Nov-08-19 02:10PM  
01:45PM  
08:14AM  
Nov-07-19 04:39PM  
Nov-06-19 10:41AM  
10:36AM  
09:52AM  
08:52AM  
Nov-05-19 10:18PM  
05:24PM  
11:17AM  
10:42AM  
Nov-04-19 04:38PM  
07:00AM  
Oct-31-19 06:53AM  
Oct-24-19 12:17PM  
08:17AM  
Oct-23-19 07:00AM  
Oct-17-19 11:20AM  
Oct-16-19 08:45AM  
Oct-11-19 10:58AM  
Oct-07-19 05:57PM  
06:41AM  
Oct-03-19 10:59AM  
09:42AM  
Sep-30-19 08:00PM  
07:00AM  
Sep-27-19 11:03AM  
Sep-26-19 11:16AM  
09:00AM  
07:00AM  
Sep-25-19 08:34AM  
Sep-23-19 01:20PM  
12:36PM  
Sep-20-19 11:54AM  
03:05AM  
03:00AM  
Sep-18-19 08:13AM  
Sep-13-19 11:38AM  
Sep-12-19 08:40AM  
07:08AM  
Sep-10-19 11:46AM  
04:56AM  
Sep-09-19 09:50AM  
Sep-03-19 08:35AM  
Aug-29-19 09:50AM  
Aug-27-19 09:00AM  
Aug-26-19 07:33PM  
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chung ChristineSVP, China OperationsMar 19Option Exercise25.407,345186,563166,358Mar 19 07:55 PM
KEARNS THOMAS F JRDirectorMar 19Option Exercise2.9018,00052,200161,464Mar 23 05:37 PM
KEARNS THOMAS F JRDirectorMar 19Sale23.1718,000417,074143,464Mar 23 05:37 PM
Chung ChristineSVP, China OperationsMar 19Sale25.917,345190,282159,013Mar 19 07:55 PM
Chung ChristineSVP, China OperationsMar 18Option Exercise25.4040010,160162,918Mar 19 07:55 PM
Chung ChristineSVP, China OperationsMar 18Sale24.793,90596,799159,013Mar 19 07:55 PM
Yu K PeonyChief Medical OfficerMar 16Option Exercise19.393,75072,713166,541Mar 18 08:05 PM
Cotroneo PatSVP, Finance and CFOMar 16Sale26.369,239243,540236,466Mar 18 08:00 PM
Chung ChristineSVP, China OperationsFeb 12Option Exercise25.405,625142,875138,269Feb 13 05:36 PM
Chung ChristineSVP, China OperationsFeb 12Sale45.985,625258,617132,644Feb 13 05:36 PM
Chung ChristineSVP, China OperationsFeb 11Option Exercise25.405,625142,875138,269Feb 13 05:36 PM
Chung ChristineSVP, China OperationsFeb 11Sale44.485,625250,200132,644Feb 13 05:36 PM
Kurkijarvi KaleviDirectorFeb 10Option Exercise18.346,000110,04034,400Feb 12 09:52 PM
Kurkijarvi KaleviDirectorFeb 10Sale42.696,000256,14028,400Feb 12 09:52 PM
Chung ChristineSVP, China OperationsJan 07Option Exercise25.405,625142,875138,269Jan 08 09:12 PM
Chung ChristineSVP, China OperationsJan 07Sale42.765,625240,525132,644Jan 08 09:12 PM
Chung ChristineSVP, China OperationsJan 06Option Exercise25.405,625142,875138,269Jan 08 09:12 PM
Kurkijarvi KaleviDirectorJan 06Option Exercise18.006,000108,00034,400Jan 08 09:14 PM
Kurkijarvi KaleviDirectorJan 06Sale42.666,000255,96028,400Jan 08 09:14 PM
Chung ChristineSVP, China OperationsJan 06Sale42.985,625241,763132,644Jan 08 09:12 PM
Cotroneo PatSVP, Finance and CFODec 20Option Exercise7.8156,254439,427310,042Dec 26 04:25 PM
Cotroneo PatSVP, Finance and CFODec 20Sale45.6759,4562,715,517250,586Dec 26 04:25 PM
Chung ChristineSVP, China OperationsDec 17Option Exercise25.405,625142,875138,269Dec 18 08:33 PM
Chung ChristineSVP, China OperationsDec 17Sale46.985,625264,244132,644Dec 18 08:33 PM
Chung ChristineSVP, China OperationsDec 16Option Exercise25.402,12053,848138,269Dec 18 08:33 PM
Yu K PeonyChief Medical OfficerDec 16Sale46.683,420159,646172,617Dec 17 08:38 PM
Chung ChristineSVP, China OperationsDec 16Sale47.085,625264,832132,644Dec 18 08:33 PM
Kurkijarvi KaleviDirectorDec 09Option Exercise18.006,000108,00034,400Dec 12 06:08 PM
Kurkijarvi KaleviDirectorDec 09Sale47.506,000285,00028,400Dec 12 06:08 PM
Yu K PeonyChief Medical OfficerDec 04Option Exercise17.464,15772,576179,397Dec 06 07:51 PM
Chung ChristineSVP, China OperationsNov 14Option Exercise21.845,625122,838145,253Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 14Sale34.745,625195,440139,628Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 13Option Exercise19.395,625109,069145,253Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 13Sale34.545,625194,288139,628Nov 15 06:07 PM
Cotroneo PatSVP, Finance and CFONov 08Option Exercise2.9012,50036,250256,932Nov 12 09:15 PM
Kurkijarvi KaleviDirectorNov 07Option Exercise9.786,00058,65034,400Nov 08 06:05 PM
Kurkijarvi KaleviDirectorNov 07Sale38.276,000229,62428,400Nov 08 06:05 PM
Chung ChristineSVP, China OperationsOct 09Option Exercise19.395,625109,069145,253Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 09Sale36.585,625205,763139,628Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 08Option Exercise19.395,625109,069145,253Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 08Sale36.785,625206,914139,628Oct 10 07:57 PM
Kurkijarvi KaleviDirectorOct 07Option Exercise9.786,00058,65034,400Oct 09 08:26 PM
Kurkijarvi KaleviDirectorOct 07Sale36.736,000220,38028,400Oct 09 08:26 PM
Chung ChristineSVP, China OperationsSep 20Option Exercise19.395,625109,069145,253Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 20Sale39.875,625224,269139,628Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 19Option Exercise19.392,12041,107145,253Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 19Sale40.455,625227,550139,628Sep 23 06:57 PM
Cotroneo PatSVP, Finance and CFOSep 17Sale41.383,201132,457244,432Sep 18 07:42 PM
Yu K PeonyChief Medical OfficerSep 16Sale40.923,419139,905175,240Sep 18 07:45 PM
Kurkijarvi KaleviDirectorSep 09Option Exercise5.956,00035,70034,400Sep 10 08:29 PM
Kurkijarvi KaleviDirectorSep 09Sale40.956,000245,72328,400Sep 10 08:29 PM
Chung ChristineSVP, China OperationsAug 23Option Exercise19.395,625109,069157,195Aug 26 07:33 PM
Chung ChristineSVP, China OperationsAug 23Sale42.515,625239,099151,570Aug 26 07:33 PM
Neff Thomas BChief Executive OfficerAug 22Option Exercise2.906,83419,8192,345,012Aug 23 04:49 PM
Chung ChristineSVP, China OperationsAug 22Option Exercise19.395,625109,069157,195Aug 26 07:33 PM
Chung ChristineSVP, China OperationsAug 22Sale43.845,625246,583151,570Aug 26 07:33 PM
Neff Thomas BChief Executive OfficerAug 22Sale43.771,41862,06644,238Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 22Sale43.8718,400807,1292,326,612Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Option Exercise2.906,83419,8192,356,578Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Sale44.811,41863,54145,656Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Sale44.7918,400824,1362,338,178Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 13Option Exercise2.906,83419,8192,368,144Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 13Sale45.611,41864,68047,074Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 13Sale45.6518,400840,0062,349,744Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Option Exercise2.906,83419,8192,379,710Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Sale45.171,41864,05648,492Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Sale45.2418,400832,3292,361,310Aug 14 05:38 PM
Kurkijarvi KaleviDirectorAug 05Option Exercise3.506,00021,00034,400Aug 07 04:42 PM
Kurkijarvi KaleviDirectorAug 05Sale45.226,000271,32028,400Aug 07 04:42 PM
Neff Thomas BChief Executive OfficerJul 25Option Exercise2.906,83419,8192,391,276Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 25Sale46.881,41866,47249,910Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 25Sale46.9518,400863,8582,372,876Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Option Exercise2.906,83419,8192,402,842Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Sale46.571,41866,03651,328Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Sale46.5418,400856,3362,384,442Jul 26 05:31 PM
Chung ChristineSVP, China OperationsJul 11Option Exercise28.215,625158,663157,195Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 11Option Exercise2.906,83419,8192,414,408Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 11Sale45.091,41863,93852,746Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 11Sale45.1518,400830,8362,396,008Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 11Sale45.145,625253,915151,570Jul 12 04:23 PM
Chung ChristineSVP, China OperationsJul 10Option Exercise29.665,625166,838157,195Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 10Option Exercise2.906,83419,8192,425,974Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 10Sale44.811,41863,54154,164Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 10Sale44.8018,400824,3002,407,574Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 10Sale44.795,625251,953151,570Jul 12 04:23 PM
Kurkijarvi KaleviDirectorJul 08Option Exercise3.506,00021,00034,400Jul 10 08:18 PM
Kurkijarvi KaleviDirectorJul 08Sale42.606,000255,57028,400Jul 10 08:18 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyJun 28Sale45.002,873129,285109,199Jul 02 08:11 PM
Neff Thomas BChief Executive OfficerJun 20Option Exercise2.906,83419,8192,437,540Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 20Sale44.3918,400816,8202,419,140Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 20Sale44.321,41862,84055,582Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 19Option Exercise2.906,83419,8192,449,106Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 19Option Exercise29.665,625166,838157,195Jun 20 06:15 PM
Chung ChristineSVP, China OperationsJun 19Sale44.025,625247,613151,570Jun 20 06:15 PM
Neff Thomas BChief Executive OfficerJun 19Sale44.0218,400809,9682,430,706Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 19Sale43.991,41862,37857,000Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 18Option Exercise29.662,12062,879157,195Jun 20 06:15 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyJun 18Option Exercise14.5816,000233,200112,072Jun 20 06:19 PM
Cotroneo PatSVP, Finance and CFOJun 18Sale43.123,201138,027250,777Jun 20 06:18 PM
Chung ChristineSVP, China OperationsJun 18Sale44.085,625247,950151,570Jun 20 06:15 PM